Surface expression of TGFβ docking receptor GARP promotes oncogenesis and immune tolerance in breast cancer

Cancer Research

Volumn 76, Issue 24, 2016, Pages 7106-7117

  Metelli, Alessandra ^a   Wu, Bill X ^a   Fugle, Caroline W ^a   Rachidi, Saleh ^a   Sun, Shaoli ^a   Zhang, Yongliang ^a   Wu, Jennifer ^a   Tomlinson, Stephen ^a   Howe, Philip H ^a   Yang, Yi ^a   Garrett Mayer, Elizabeth ^a   Liu, Bei ^a   Li, Zihai ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN GARP; TRANSFORMING GROWTH FACTOR BETA; TUMOR PROTEIN; UNCLASSIFIED DRUG; LRRC32 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; LUNG CANCER; MALIGNANT TRANSFORMATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR ESCAPE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOGENESIS; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE;

EID: 85006870995     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1456     Document Type: Article

References (49)

1. Szepetowski P, Ollendorff V, Grosgeorge J, Courseaux A, Birnbaum D, Theillet C, et al. DNA amplification at 11q13.5-q14 in human breast cancer. Oncogene 1992;7:2513-7.
2. Ollendorff V, Noguchi T, deLapeyriere O, Birnbaum D. The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins. Cell Growth Differ 1994;5:213-9.
3. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 2009;106:13439-44.
4. Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D. Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PLoS One 2008;3:e2705.
5. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 2009;106:13445-50.
6. Wang R, Zhu J, Dong X, Shi M, Lu C, Springer TA. GARP regulates the bioavailability and activation of TGFβ. Mol Biol Cell 2012;23:1129-39.
7. Stockis J, Colau D, Coulie PG, Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 2009;39:3315-22.
8. Edwards JP, Fujii H, Zhou AX, Creemers J, Unutmaz D, Shevach EM. Regulation of the expression of GARP/latent TGF-β1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation. J Immunol 2013;190:5506-15.
9. Hahn SA, Stahl HF, Becker C, Correll A, Schneider FJ, Tuettenberg A, et al. Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4(+) T cells. Blood 2013;122:1182-91.
10. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
11. Massague J. TGFbeta in cancer. Cell 2008;134:215-30.
12. Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998;8:1243-52.
13. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001;12:27-36.
14. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986;83:4167-71.
15. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994;269:6271-4.
16. Sunderkotter C, Goebeler M, Schulze-Osthoff K, Bhardwaj R, Sorg C. Macrophage-derived angiogenesis factors. Pharmacol Ther 1991;51:195-216.
17. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986;163:1037-50.
18. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009;69:7775-83.
19. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008;134:392-404.
20. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003;100:8430-5.
21. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008;133:66-77.
22. Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, et al. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest 2013;123:3925-40.
23. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-20.
24. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 2013;210:2435-66.
25. Tran DQ. TGF-β: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol 2012;4:29-37.
26. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-76.
27. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 1989;109:309-15.
28. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990;110:1361-7.
29. Fridrich S, Hahn SA, Linzmaier M, Felten M, Zwarg J, Lennerz V, et al. How soluble GARP enhances TGFβ activation. PLoS One 2016;11:e0153290.
30. Gauthy E, Cuende J, Stockis J, Huygens C, Lethe B, Collet JF, et al. GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells. PLoS One 2013;8:e76186.
31. Randow F, Seed B. Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat Cell Biol 2001;3:891-6.
32. Hussey GS, Chaudhury A, Dawson AE, Lindner DJ, Knudsen CR, Wilce MC, et al. Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol Cell 2011;41:419-31.
33. Rachidi SM, Qin T, Sun S, Zheng WJ, Li Z. Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PLoS One 2013;8:e57911.
34. Wu S, Hong F, Gewirth D, Guo B, Liu B, Li Z. The molecular chaperone gp96/GRP94 interacts with Toll-like receptors and integrins via its C-terminal hydrophobic domain. J Biol Chem 2012;287:6735-42.
35. Hong F, Liu B, Chiosis G, Gewirth DT, Li Z. a7 helix region of alphaI domain is crucial for integrin binding to endoplasmic reticulum chaperone gp96: a potential therapeutic target for cancer metastasis. J Biol Chem 2013;288:18243-8.
36. Zhang Y, Wu BX, Metelli A, Thaxton JE, Hong F, Rachidi S, et al. GP96 is a GARP chaperone and controls regulatory T cell functions. J Clin Invest 2015;125:859-69.
37. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
38. Howley BV, Hussey GS, Link LA, Howe PH. Translational regulation of inhibin βA by TGFβ via the RNA-binding protein hnRNP E1 enhances the invasiveness of epithelial-to-mesenchymal transitioned cells. Oncogene 2016;35:1725-35.
39. Xie L, Law BK, Aakre ME, Edgerton M, Shyr Y, Bhowmick NA, et al. Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res 2003;5:R187-98.
40. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009;19:156-72.
41. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. In: Coligan JE, Bierer BE, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology. Hoboken, New Jersey: Wiley; 2001.
42. McHugh RS, Shevach EM. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002;168:5979-83.
43. Dai J, Liu B, Ngoi SM, Sun S, Vella AT, Li Z. TLR4 hyperresponsiveness via cell surface expression of heat shock protein gp96 potentiates suppressive function of regulatory T cells. J Immunol 2007;178:3219-25.
44. Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, et al. Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer. PLoS One 2014;9:e85398.
45. Baker K, Raut P, Jass JR. Colorectal cancer cells express functional cell surface-bound TGFβ. Int J Cancer 2008;122:1695-700.
46. Ahn YO, Lee JC, Sung MW, Heo DS. Presence of membrane-bound TGF-beta1 and its regulation by IL-2-activated immune cell-derived IFN-gamma in head and neck squamous cell carcinoma cell lines. J Immunol 2009;182:6114-20.
47. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010;10:554-67.
48. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-11.
49. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012;11:790-811.